

# Roberto Eleopra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5284525/publications.pdf>

Version: 2024-02-01

142  
papers

5,579  
citations

76196

40  
h-index

98622

67  
g-index

156  
all docs

156  
docs citations

156  
times ranked

6476  
citing authors

#	ARTICLE	IF	CITATIONS
1	Short- and long-term motor outcome of ÅSTN-DBS in Parkinsonâ€™s Disease: focus on sex differences. <i>Neurological Sciences</i> , 2022, 43, 1769-1781.	0.9	15
2	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldtâ€™Jakob Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 848991.	1.7	4
3	The Alpha-Synuclein RT-QuIC Products Generated by the Olfactory Mucosa of Patients with Parkinsonâ€™s Disease and Multiple System Atrophy Induce Inflammatory Responses in SH-SY5Y Cells. <i>Cells</i> , 2022, 11, 87.	1.8	5
4	Cerebrospinal fluid neuropathological biomarkers in beta-propeller protein-associated neurodegeneration, with complicated parkinsonian phenotype. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 38-40.	1.1	0
5	Globus pallidus internus activity during simultaneous bilateral microelectrode recordings in status dystonicus. <i>Acta Neurochirurgica</i> , 2021, 163, 211-217.	0.9	3
6	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of âœœorganicâœ•neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.	1.7	45
7	Neuroimaging in idiopathic adult-onset focal dystonia. <i>Neurological Sciences</i> , 2021, 42, 2947-2950.	0.9	3
8	An intra-operative feature-based classification of microelectrode recordings to support the subthalamic nucleus functional identification during deep brain stimulation surgery. <i>Journal of Neural Engineering</i> , 2021, 18, 016003.	1.8	3
9	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 182-192.	4.9	74
10	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. <i>Neurological Sciences</i> , 2021, 42, 2637-2644.	0.9	18
11	Functional motor phenotypes: to lump or to split?. <i>Journal of Neurology</i> , 2021, 268, 4737-4743.	1.8	25
12	Globus Pallidus Internus Deep Brain Stimulation Using Frame-Based vs. Frameless Stereotaxy in Dystonia: A Single-Center Experience. <i>Frontiers in Neurology</i> , 2021, 12, 643757.	1.1	2
13	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 70-74.	1.1	8
14	A video of best practice recommendations for making botulinum toxin therapy safe during the COVID-19 pandemic. <i>Neurological Sciences</i> , 2021, 42, 3937-3938.	0.9	1
15	Functional gait disorders: Demographic and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 32-36.	1.1	4
16	Levodopaâ€™carbidopa intrajejunal infusion in Parkinsonâ€™s disease: untangling the role of age. <i>Journal of Neurology</i> , 2021, 268, 1728-1737.	1.8	9
17	A New Implantable Closed-Loop Clinical Neural Interface: First Application in Parkinsonâ€™s Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 763235.	1.4	24
18	Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. <i>Molecular Neurodegeneration</i> , 2021, 16, 82.	4.4	28

#	ARTICLE	IF	CITATIONS
19	Managing Parkinson's disease: moving ON with NOP. <i>British Journal of Pharmacology</i> , 2020, 177, 28-47.	2.7	11
20	Parkinsonism and Nigrostriatal Damage Secondary to <i>CSF1R</i> -Related Primary Microgliopathy. <i>Movement Disorders</i> , 2020, 35, 2360-2362.	2.2	6
21	Comparison of 123I-MIBG scintigraphy and phosphorylated $\alpha$ -synuclein skin deposits in synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 48-53.	1.1	22
22	<i>GBA</i> -Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020, 35, 2106-2111.	2.2	83
23	Idiopathic Non-task-Specific Upper Limb Dystonia, a Neglected Form of Dystonia. <i>Movement Disorders</i> , 2020, 35, 2038-2045.	2.2	21
24	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.	0.8	45
25	Characterization of Microelectrode Recordings for the Subthalamic Nucleus identification in Parkinson's disease. , 2020, 2020, 3485-3488.		1
26	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. <i>Journal of Neural Transmission</i> , 2020, 127, 1435-1439.	1.4	22
27	Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. <i>Frontiers in Neurology</i> , 2020, 11, 906.	1.1	6
28	Lessons from the present: Intraoperative neurophysiological monitoring organization during the COVID-19 pandemic in Lombardy, northern Italy. <i>Clinical Neurophysiology</i> , 2020, 131, 2056-2058.	0.7	2
29	Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease With Orthostatic Hypotension. <i>Movement Disorders</i> , 2020, 35, 1649-1657.	2.2	50
30	Clinical duration of action of different botulinum toxin types in humans. <i>Toxicon</i> , 2020, 179, 84-91.	0.8	24
31	Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 130-132.	1.1	30
32	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 40-43.	1.1	18
33	Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. <i>Neurological Sciences</i> , 2020, 41, 2781-2792.	0.9	8
34	Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson's Disease?. <i>Movement Disorders</i> , 2020, 35, 1379-1387.	2.2	8
35	Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based Case-Control Study. <i>Movement Disorders</i> , 2020, 35, 1287-1292.	2.2	148
36	Efficient RT-QuIC seeding activity for $\alpha$ -synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. <i>Translational Neurodegeneration</i> , 2019, 8, 24.	3.6	106

#	ARTICLE	IF	CITATIONS
37	Spatio-temporal structure of single neuron subthalamic activity identifies DBS target for anesthetized Tourette syndrome patients. <i>Journal of Neural Engineering</i> , 2019, 16, 066011.	1.8	23
38	Is Deep Brain Stimulation still an option for tremor recurrence after Focused Ultrasound thalamotomy? A case report. <i>Journal of Clinical Neuroscience</i> , 2019, 68, 344-346.	0.8	11
39	Brain impedance variation of directional leads implanted in subthalamic nuclei of Parkinsonian patients. <i>Clinical Neurophysiology</i> , 2019, 130, 1562-1569.	0.7	10
40	Diagnostic criteria for small fibre neuropathy in clinical practice and research. <i>Brain</i> , 2019, 142, 3728-3736.	3.7	111
41	Food knowledge depends upon the integrity of both sensory and functional properties: a VBM, TBSS and DTI tractography study. <i>Scientific Reports</i> , 2019, 9, 7439.	1.6	8
42	Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. <i>Journal of Neurology</i> , 2019, 266, 2164-2176.	1.8	42
43	Validated outcome of treatment changes according to International League Against Epilepsy criteria in adults with drug-resistant focal epilepsy. <i>Epilepsia</i> , 2019, 60, 1114-1123.	2.6	23
44	Deep brain stimulation of the subthalamic nucleus and the temporal discounting of primary and secondary rewards. <i>Journal of Neurology</i> , 2019, 266, 1113-1119.	1.8	8
45	Frameless Deep Brain Stimulation Surgery: A Single-Center Experience and Retrospective Analysis of Placement Accuracy of 220 Electrodes in a Series of 110 Patients. <i>Stereotactic and Functional Neurosurgery</i> , 2019, 97, 337-346.	0.8	4
46	The Surgical Approach to the Anterior Nucleus of Thalamus in Patients With Refractory Epilepsy: Experience from the International Multicenter Registry (MORE). <i>Neurosurgery</i> , 2019, 84, 141-150.	0.6	57
47	Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients. <i>Neurobiology of Aging</i> , 2018, 66, 179.e5-179.e16.	1.5	16
48	The epidemiology of Parkinson's disease in the Italian region Friuli Venezia Giulia: a population-based study with administrative data. <i>Neurological Sciences</i> , 2018, 39, 699-704.	0.9	14
49	Effect of thymectomy on refractory autoimmune status epilepticus. <i>Journal of Neuroimmunology</i> , 2018, 317, 90-94.	1.1	13
50	CHA2DS2-VASc score predicts short- and long-term outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 122-129.	1.0	2
51	A population-based study of injuries to the brachial plexus and to the peripheral nerves of the shoulder girdle and upper limb in the Italian region Friuli Venezia Giulia. <i>Neurosurgical Review</i> , 2018, 41, 519-523.	1.2	1
52	Neurophysiologic profile in muscular reinnervation of different botulinum toxins in humans. <i>Toxicon</i> , 2018, 156, S23.	0.8	0
53	AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study. <i>Toxins</i> , 2018, 10, 448.	1.5	8
54	Spread of dystonia in patients with idiopathic adult-onset laryngeal dystonia. <i>European Journal of Neurology</i> , 2018, 25, 1341-1344.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Introduction of direct oral anticoagulant within 7 days of stroke onset: a nomogram to predict the probability of 3-month modified Rankin Scale score $\geq 2$ . <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 292-298.	1.0	10
56	Effect of Mindfulness Meditation on Personality and Psychological Well-being in Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018, 20, 101-108.	0.4	23
57	<i>COL6A5</i> variants in familial neuropathic chronic itch. <i>Brain</i> , 2017, 140, aww343.	3.7	25
58	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 90-92.	1.1	44
59	The Italian Dystonia Registry: rationale, design and preliminary findings. <i>Neurological Sciences</i> , 2017, 38, 819-825.	0.9	35
60	Weight gain after STN-DBS: The role of reward sensitivity and impulsivity. <i>Cortex</i> , 2017, 92, 150-161.	1.1	28
61	Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. <i>Pharmacological Reviews</i> , 2017, 69, 200-235.	7.1	506
62	Prevalence of Neuropathic Pain in Patients with Traumatic Brachial Plexus Injury: A Multicenter Prospective Hospital-Based Study. <i>Pain Medicine</i> , 2017, 18, 2428-2432.	0.9	37
63	Short and long-term outcomes after combined intravenous thrombolysis and mechanical thrombectomy versus direct mechanical thrombectomy: a prospective single-center study. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 203-209.	1.0	30
64	Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). <i>BMJ Open</i> , 2017, 7, e015434.	0.8	14
65	A new potential biomarker for dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 318-326.	1.5	92
66	Quantitative Diffusion Tensor Imaging Analysis of Low-Grade Gliomas: From Preclinical Application to Patient Care. <i>World Neurosurgery</i> , 2017, 97, 333-343.	0.7	11
67	Post-anoxic status epilepticus: which variable could modify prognosis? A single-center experience. <i>Minerva Anestesiologica</i> , 2017, 83, 1255-1264.	0.6	4
68	Chronic pain in Gaucher disease: skeletal or neuropathic origin?. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 148.	1.2	18
69	Formal Semantics in the Neurology Clinic: Atypical Understanding of Aspectual Coercion in ALS Patients. <i>Frontiers in Psychology</i> , 2016, 7, 1733.	1.1	4
70	Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. <i>European Journal of Neurology</i> , 2016, 23, 190-195.	1.7	41
71	Levodopa/carbidopa intestinal gel therapy for advanced Parkinson Disease: AN early toxic effect for small nerve fibers?. <i>Muscle and Nerve</i> , 2016, 54, 970-972.	1.0	18
72	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 108-115.	1.1	22

#	ARTICLE	IF	CITATIONS
73	Stroke Severity Is a Crucial Predictor of Outcome: An International Prospective Validation Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	152
74	Referring Parkinson's disease patients for deep brain stimulation: a RAND/UCLA appropriateness study. <i>Journal of Neurology</i> , 2016, 263, 112-119.	1.8	23
75	Clinical outcome of deep brain stimulation for dystonia: constant current or constant voltage stimulation? A non-randomized study. <i>European Journal of Neurology</i> , 2015, 22, 919-926.	1.7	45
76	Second Surgery in Insular Low-Grade Gliomas. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	13
77	Side and time variability of intraepidermal nerve fiber density. <i>Neurology</i> , 2015, 84, 2368-2371.	1.5	29
78	Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 879-886.	0.9	32
79	Taking care of patients with brain tumor-related epilepsy: results from an Italian survey. <i>Neurological Sciences</i> , 2015, 36, 125-130.	0.9	7
80	The Use of Antidepressant Medication before and after the Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Cohort Study. <i>Neuroepidemiology</i> , 2015, 44, 91-98.	1.1	16
81	Body weight and food intake in Parkinson's disease. A review of the association to non-motor symptoms. <i>Appetite</i> , 2015, 84, 204-211.	1.8	44
82	The processing of actions and action-words in amyotrophic lateral sclerosis patients. <i>Cortex</i> , 2015, 64, 136-147.	1.1	30
83	Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 490-495.	0.9	55
84	Surgery for insular low-grade glioma: predictors of postoperative seizure outcome. <i>Journal of Neurosurgery</i> , 2014, 120, 12-23.	0.9	61
85	Facial and Bodily Emotion Recognition in Multiple Sclerosis: The Role of Alexithymia and Other Characteristics of the Disease. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 1004-1014.	1.2	44
86	Effects of an 8-week meditation program on the implicit and explicit attitudes toward religious/spiritual self-representations. <i>Consciousness and Cognition</i> , 2014, 30, 266-280.	0.8	43
87	Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. <i>Movement Disorders</i> , 2014, 29, 229-237.	2.2	239
88	Cognitive and brain reserve for mind-body therapeutic approaches in multiple sclerosis: A review. <i>Restorative Neurology and Neuroscience</i> , 2014, 32, 575-595.	0.4	17
89	Chronic post-traumatic neuropathic pain of brachial plexus and upper limb: a new technique of peripheral nerve stimulation. <i>Neurosurgical Review</i> , 2014, 37, 473-480.	1.2	39
90	Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1273-1280.	2.2	200

#	ARTICLE	IF	CITATIONS
91	Emotion recognition in Parkinson's disease after subthalamic deep brain stimulation: Differential effects of microlesion and STN stimulation. <i>Cortex</i> , 2014, 51, 35-45.	1.1	22
92	Paroxysmal itch caused by gain-of-function Nav1.7 mutation. <i>Pain</i> , 2014, 155, 1702-1707.	2.0	78
93	Microsubthalamotomy improves sleep in patients affected by advanced Parkinson's disease. <i>Sleep Medicine</i> , 2014, 15, 637-641.	0.8	18
94	To move or not to move: Subthalamic deep brain stimulation effects on implicit motor simulation. <i>Brain Research</i> , 2014, 1574, 14-25.	1.1	15
95	Different types of botulinum neurotoxins in mouse and human neuromuscular junction. <i>Toxicon</i> , 2013, 75, 222.	0.8	0
96	Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study. <i>Clinical Neurophysiology</i> , 2013, 124, 999-1004.	0.7	37
97	The effects of healthy aging on mental imagery as revealed by egocentric and allocentric mental spatial transformations. <i>Acta Psychologica</i> , 2013, 143, 146-156.	0.7	23
98	The Incidence of Amyotrophic Lateral Sclerosis in Friuli Venezia Giulia, Italy, from 2002 to 2009: A Retrospective Population-Based Study. <i>Neuroepidemiology</i> , 2013, 41, 54-61.	1.1	20
99	A New Rechargeable Device for Deep Brain Stimulation: A Prospective Patient Satisfaction Survey. <i>European Neurology</i> , 2013, 69, 193-199.	0.6	50
100	Surgery of Insular Nonenhancing Gliomas. <i>Neurosurgery</i> , 2012, 70, 1081-1094.	0.6	97
101	Action and Language Processing in Patients with Motor Neuron Disease. <i>Procedia, Social and Behavioral Sciences</i> , 2012, 61, 4.	0.5	0
102	The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 775-780.	1.1	58
103	Deep brain stimulation: Subthalamic nucleus electrophysiological activity in awake and anesthetized patients. <i>Clinical Neurophysiology</i> , 2012, 123, 2406-2413.	0.7	58
104	Environmental risk factors and clinical phenotype in familial and sporadic primary blepharospasm. <i>Neurology</i> , 2011, 77, 631-637.	1.5	42
105	Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease. <i>Movement Disorders</i> , 2010, 25, 1723-1732.	2.2	37
106	Efficacy of botulinum toxin type A treatment of functional impairment of degenerative hip joint: Preliminary results. <i>Journal of Rehabilitation Medicine</i> , 2010, 42, 691-693.	0.8	12
107	Progressive multifocal leukoencephalopathy in a patient with Good's syndrome. <i>International Journal of Infectious Diseases</i> , 2010, 14, e444-e447.	1.5	16
108	Biology and Clinical Pharmacology of Botulinum Neurotoxin Type C and Other Non-A/Non-B Botulinum Neurotoxins. , 2009, , 77-84.		0



#	ARTICLE	IF	CITATIONS
109	Pallidal stimulation for segmental dystonia: Long term follow up of 11 consecutive patients. <i>Movement Disorders</i> , 2009, 24, 1829-1835.	2.2	52
110	Unusual Parsonageâ€“Turner syndrome with relapses and bilateral simultaneous anterior interosseous neuropathy. <i>Neurological Sciences</i> , 2009, 30, 513-516.	0.9	12
111	A decision tool to support appropriate referral for deep brain stimulation in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2009, 256, 83-88.	1.8	44
112	Effect of slow rTMS of motor cortex on the excitability of the Blink Reflex: A study in healthy humans. <i>Clinical Neurophysiology</i> , 2009, 120, 174-180.	0.7	14
113	The arginine growth hormone stimulation test in bradykineticâ€“rigid parkinsonisms. <i>Movement Disorders</i> , 2008, 23, 190-194.	2.2	11
114	Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: Case study and effect of deep brain stimulation. <i>Movement Disorders</i> , 2008, 23, 114-118.	2.2	30
115	Botulinum Toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. <i>Pain</i> , 2007, 130, 76-83.	2.0	66
116	Deep brain stimulation in the management of multiple sclerosis tremor. <i>Neurological Sciences</i> , 2006, 27, s331-s334.	0.9	2
117	Clinical use of non-a botulinum toxins: botulinum toxin type B. <i>Neurotoxicity Research</i> , 2006, 9, 121-125.	1.3	62
118	Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F. <i>Neurotoxicity Research</i> , 2006, 9, 127-131.	1.3	49
119	Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test. <i>Annals of Neurology</i> , 2006, 60, 611-615.	2.8	36
120	The excitability of the trigeminal motor system in sleep bruxism: a transcranial magnetic stimulation and brainstem reflex study. <i>Journal of Orofacial Pain</i> , 2006, 20, 145-55.	1.7	21
121	Different types of botulinum toxin in humans. <i>Movement Disorders</i> , 2004, 19, S53-S59.	2.2	109
122	Explosive-aggressive behavior related to bilateral subthalamic stimulation. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 247-251.	1.1	83
123	Analysis of the ?-sarcoglycan gene in familial and sporadic myoclonus-dystonia: Evidence for genetic heterogeneity. <i>Movement Disorders</i> , 2003, 18, 1047-1051.	2.2	58
124	Recovery cycle of the masseter inhibitory reflex after magnetic stimulation in normal subjects. <i>Clinical Neurophysiology</i> , 2003, 114, 1253-1258.	0.7	5
125	Neurophysiological study of corticomotor pathways in restless legs syndrome. <i>Clinical Neurophysiology</i> , 2003, 114, 1638-1645.	0.7	61
126	Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting. <i>Clinical Neurophysiology</i> , 2002, 113, 1258-1264.	0.7	37



#	ARTICLE	IF	CITATIONS
127	The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A. <i>Clinical Autonomic Research</i> , 2002, 12, 174-178.	1.4	49
128	Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. <i>British Journal of Dermatology</i> , 2002, 147, 808-809.	1.4	88
129	Management of Parotid Sialocele With Botulinum Toxin. <i>Laryngoscope</i> , 1999, 109, 1344-1346.	1.1	58
130	Hyperhidrosis and sympathetic skin response in chronic alcoholic patients. <i>Clinical Autonomic Research</i> , 1999, 9, 17-22.	1.4	13
131	On the action of botulinum neurotoxins A and E at cholinergic terminals. <i>Journal of Physiology (Paris)</i> , 1998, 92, 135-139.	2.1	13
132	Italian multicentre study of carpal tunnel syndrome: study design. <i>Italian Journal of Neurological Sciences</i> , 1998, 19, 285-289.	0.1	27
133	Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. <i>Neuroscience Letters</i> , 1998, 256, 135-138.	1.0	184
134	The therapeutic use of botulinum toxin. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 1383-1394.	1.9	21
135	Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. <i>Neuroscience Letters</i> , 1997, 224, 91-94.	1.0	132
136	The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans. <i>Movement Disorders</i> , 1997, 12, 89-94.	2.2	113
137	Botulinum toxin treatment in the facial muscles of humans. <i>Neurology</i> , 1996, 46, 1158-1160.	1.5	85
138	Cryoglobulinemic neuropathy related to hepatitis C virus infection. Clinical, laboratory and neurophysiological study. <i>Journal of the Peripheral Nervous System</i> , 1996, 1, 131-8.	1.4	16
139	Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. <i>Italian Journal of Neurological Sciences</i> , 1993, 14, 361-367.	0.1	36
140	Unusual case of Fahr syndrome with motoneuron disease. <i>Italian Journal of Neurological Sciences</i> , 1991, 12, 597-600.	0.1	5
141	Motor neuron disease in the province of Ferrara, Italy, in 1964-1982. <i>Neurology</i> , 1988, 38, 1604-1604.	1.5	107
142	Use of Non-A/Non-B Botulinum Toxins. , 0, , 137-138.		0